Medical Scientist Training Program  http://www.mstp.uab.edu    Back to Main

Faculty Detail    
Name EDWARD P ACOSTA
 
Campus Address VH 258 Zip 0019
Phone  (20-5) -655
E-mail  eacosta@uab.edu
Other websites
     


Faculty Appointment(s)
Appointment Type Department Division Rank
Secondary  Pediatrics   Pediatrics Chair Office Assistant Professor
Center  Cystic Fibrosis Research Center  Cystic Fibrosis Research Center Professor
Center  General Clinical Research Center  Ctr for Clinical & Translational Sci Professor
Center  Comprehensive Cancer Center  Comprehensive Cancer Center Professor
Center  Comp Arthritis, MSK, Bone & Autoimmunity Ctr  Comp Arthritis, MSK, Bone & Autoimmunity Ctr Professor
Primary  Pharmacology/Toxicology   Clinical Pharmacology/Toxicology Professor
Center  General Clinical Research Center  Center for Women's Reproductive Health Professor
Center  Center for AIDS Research  Center for AIDS Research Professor

Graduate Biomedical Sciences Affiliations
Integrative Biomedical Sciences 
Medical Scientist Training Program 

Biographical Sketch 
BS in Biology, University of Minnesota-Duluth; BS in Pharmacy, College of Pharmacy, Univeristy of Minnesota; Doctor of Pharmacy (Pharm.D.), College of Pharmacy, University of Minnesota; Post-Doctoral Research Fellowship; Infectious Diseases, Pharmacokinetics/Pharmacodynamics; College of Pharmacy, University of Minnesota

Society Memberships
Organization Name Position Held Org Link
American Society for Microbiology
American Society of Clinical Pharmacology and Therapeutics
International Society for Antiviral Research 
   



Research/Clinical Interest
Title
Bioanalysis and pharmacometrics of antiviral agents
Description
A primary goal of my lab is to develop assays for the quantitation of antiviral and antiretroviral drugs from plasma specimens and other unique matrices. We participate in multicenter clinical trials designed to assess the absorption and disposition of antiviral and antiretroviral drugs. The lab then quantitates these compounds from samples collected from patients in these studies and we perform pharmacokinetic and/or pharmacodynamic analyses in an attempt to better understand how these drugs should be used in adult and pediatric patient populations. Our pharmacokinetic analyses focus on noncompartmental and individual or population modeling approaches.

Selected Publications 
Publication PUBMEDID
Acosta EP, Brundage RC, King JR, Griffin J, Sánchez PJ, Sood S, Agrawal V, Homans J, Jacobs RF, Lang D, Romero JR, Griffin J, Cloud G, Whitley RJ, Kimberlin DW, for the National Institute of Allergy and Infectious Diseases’ Collaborative Antiviral Study Group. Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. Clinical Pharmacology and Therapeutics 2007;81:867-72.   
Acosta EP, Balfour Jr., HH. Acyclovir for treatment of postherpetic neuralgia: Efficacy and pharmacokinetics. Antimicrobial Agents and Chemotherapy 2001;45:2771-4.   
King JR, Nachman S, Yogev R, Aldrovandi G, Damle B, Hodge J, Wiznia A, Acosta EP, for the Pediatric AIDS Clinical Trials Group 403 Team. Single-dose pharmacokinetics of enteric-coated didanosine in HIV-infected children. Antiviral Therapy 2002;7:267-70.   
Acosta EP, Gerber JG, and the Adult ACTG Pharmacology Committee. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Research and Human Retroviruses 2002;18:825-34.    
Turner ML, Reed-Walker K, King JR, Acosta EP. Simultaneous quantitation of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma using a single high-performance liquid chromatography methodology. Journal of Chromatography B 2003;784:331-41.   
Acosta EP, Balfour HH Jr. Intermittent administration of high-dose stavudine to nucleoside-experienced individuals. Journal of Acquired Immune Deficiency Syndromes 2003;33:343-8.   
Trachte GJ, Hook PJ, Kemp JR, Acosta EP, Zeigler RJ. Thromboxane synthesis and actions in isolated adrenergic nerve (pheochromocytoma-12) cells. Journal of Pharmacology and Experimental Therapeutics 247:43-46, 1988.   
Acosta EP, King JR. Methods for integration of pharmacokinetic and phenotypic information in the treatment of HIV-Infection. Clinical Infectious Diseases 2003;36:373-7.    
Balfour Jr HH, Fletcher CV, Erice A, Henry K, Acosta EP, Smith S, Holm M, Boivin G, Shepp D, Crumpacker C, Eaton C, Martin-Munley S.. Effect of foscarnet on quantities of cytomegalovirus and human immunoodeficiency virus in blod of persons with AIDS. Antimicrobial Agents and Chemotherapy 40:2721-2726, 1996.   
Acosta EP, Bardeguez A, Zorrilla CD, Van Dyke R, Hughes MD, Huang S, Pompeo L, Stek AM, Pitt J, Watts DH, Smith E, Jiménez E, Mofenson L, and the Pediatric AIDS Clinical Trials Group 386 Protocol Team. Pharmacokinetics of saquinavir plus low-dose ritonavir in HIV-infected pregnant women. Antimicrobial Agents and Chemotherapy 2004;48:430-6.   
Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer III WA, Acosta EP, Schackman BR, Pilcher CD, Murphy RL, Maher WE, Witt MD, Reichman RC, Snyder S, Klingman KL, Kuritzkes DR, for the ACTG A5095 Protocol Team. Triple nucleoside analogue vs. efavirenz-containing regimens for the initial treatment of HIV-1 infection: AIDS Clinical Trials Group (ACTG) Study A5095. New England Journal of Medicine 2004; 350:1850-61.    

Keywords
pharmacokinetics, antivirals, antiretrovirals